CD8A and melanoma: Moreover, plasminogen activating inhibitor-1 (PAI-1), which possesses various pro-tumorigenic functions in cancer progression and metastasis, decreases CD8+ TILs through TAMs at tumor sites, leading to the development of tolerance to anti-PD1 Abs in advanced melanoma patients [17].